HU

Hutchmed (China) Limited

HCM | HKEX

Overview

Corporate Details

ISIN(s):
KYG4672N1198 (+1 more)
LEI:
2138006X34YDQ6OBYE79
Country:
Hong Kong
Address:
LEVEL 18, THE METROPOLIS TOWER, KOWLOON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

No description available.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-05 08:25
Regulatory News Service
Enrollment Complete in SAFFRON Global Phase III
English 29.9 KB
2025-11-03 08:30
Regulatory News Service
Updates from R&D Event
English 23.6 KB
2025-10-23 08:00
Regulatory News Service
HUTCHMED Presents Data at AACR NCI EORTC
English 20.4 KB
2025-10-21 10:30
Remuneration Information
Vesting of awards under Long Term Incentive Plan
English 41.6 KB
2025-10-14 10:30
Board/Management Information
Appointment of Independent Non-executive Director
English 20.0 KB
2025-10-13 08:05
Earnings Release
Data to be Presented at the 2025 ESMO Congress
English 23.1 KB
2025-10-02 08:00
Regulatory News Service
HUTCHMED Highlights Data to be Presented at ESMO
English 32.5 KB
2025-09-30 10:30
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 13.3 KB
2025-08-26 08:00
Board/Management Information
Directorate Change
English 17.9 KB
2025-08-20 08:00
Regulatory News Service
HUTCHMED Completes Enrollment of Phase III Trial
English 29.1 KB
2025-08-07 13:00
Earnings Release
2025 Interim Results
English 141.5 KB
2025-07-03 10:30
Report Publication Announcement
HUTCHMED to Announce 2025 Half-Year Results
English 12.1 KB
2025-06-30 10:30
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 12.4 KB
2025-06-30 10:30
Remuneration Information
Blocklisting Six Monthly Return
English 25.1 KB
2025-06-30 10:30
Regulatory News Service
China Approval based on Phase III SACHI Trial
English 29.8 KB

Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hutchmed (China) Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
Alkermes plc. Logo
Develops medicines for CNS disorders like schizophrenia, bipolar, and sleep disorders.
United States of America ALKS
Allarity Therapeutics, Inc. Logo
Develops personalized cancer drugs using a diagnostic platform to predict patient response.
United States of America ALLR
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX
Allogene Therapeutics, Inc. Logo
Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.
United States of America ALLO
Israel KVSR
Almirall S.A. Logo
A global biopharmaceutical company developing innovative medical solutions for skin health.
Spain ALM
ALNYLAM PHARMACEUTICALS, INC. Logo
Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.
United States of America ALNY

Talk to a Data Expert

Have a question? We'll get back to you promptly.